Overview

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

Status:
Active, not recruiting

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy of Lenalidomide/Dexamethasone + Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

AbbVie

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Elotuzumab
Lenalidomide
Thalidomide